Drug Profile
Research programme: diabetes therapy - Evotec SE/AstraZeneca
Alternative Names: DG 770; EVT 770Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator DeveloGen; MedImmune
- Developer AstraZeneca; Evotec SE
- Class Biological factors
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Germany (SC)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany (SC)
- 08 Jan 2013 EVT 770 licensed to MedImmune worldwide